IDO1 and melanoma: Unfortunately, the results of phase III trial (ECHO301) in melanoma indicated that IDO-inhibitor treatment, in combination with anti-PD-1 antibody, showed no improvement in progression-free survival compared to the anti-PD-1 antibody alone [27].